Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

View Full Paper
Ask AI
Bookmark
Share

Authors

YRYuhong RenJLJia LiuZLZhijuan Lin

Discussion

Loading...

Member takes

Overview

Multicenter study shows Pola-R-CHP achieves 93.8% complete response in low-risk DLBCL, suggesting effective treatment options.

Key Points

  • This study aims to evaluate the effectiveness of the Pola-R-CHP regimen in previously untreated low-risk DLBCL patients with an IPI score of 0-1.
  • Multicenter retrospective study conducted across 17 centers in China.
  • Patients with IPI score of 0-1 receiving Pola-R-CHP were enrolled and assessed with PET/CT scans.
  • Efficacy evaluated after treatment cycles using Lugano criteria and adverse events graded per NCI-CTCAE 5.0.
  • Complete response rate at end of treatment was 93.8%.
  • Overall response rate reached 100% at end of treatment.
  • Main adverse events included anemia (89%), leukocytopenia (61.5%), and neutropenia (51.6%).
  • Subgroup analyses indicated similar effectiveness across high-risk factors like TP53 mutations.

Cite This Study

Ren et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8efhttps://doi.org/10.1182/blood-2025-7229
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis2025
  2. 2A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025
  3. 3Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  4. 4Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study2026
  5. 5Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025